The inherent metastasis of leukaemia and its exploitation by sonodynamic therapy

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 2, 2015, Pages 149-163

  Trendowski, Matthew ^a  

^a SYRACUSE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Drug resistance; Leukaemia; Leukocytes; Metastasis; Sonodynamic therapy; Ultrasound

Indexed keywords

CYTOCHALASIN B; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; FLUOROURACIL;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; EXTRACORPOREAL BLOOD SONICATION; EXTRAVASATION; HEMATOPOIETIC STEM CELL; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IN VIVO STUDY; INTRAVASATION; LARGE CELL LYMPHOMA; LEUKEMIA; MACROPHAGE; METASTASIS; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NONHUMAN; PHENOTYPE; PHOTODYNAMIC THERAPY; PHYSICAL MEDICINE; REVIEW; SONODYNAMIC THERAPY; ULTRASOUND THERAPY; VASCULAR DISEASE; ANIMAL; PATHOLOGY; PROCEDURES;

ANIMALS; HUMANS; LEUKEMIA; NEOPLASM METASTASIS; ULTRASONIC THERAPY;

EID: 84925946267     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.12.013     Document Type: Review

References (78)

1. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006, 6(6):449-458.
2. Leber M.F., Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol 2009, 34(4):881-895.
3. Mareel M., Leroy A. Clinical: cellular, and molecular aspects of cancer invasion. Physiol Rev 2003, 83(2):337-376.
4. Yokota J. Tumor progression and metastasis. Carcinogenesis 2000, 21(March (3)):497-503.
5. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA: Cancer J Clin 2014, 64(1):9-29.
6. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3(6):453-458.
7. Weinberg R.A. The Biology of Cancer 2013, Garland Science, New York. 2nd ed.
8. Divoli A., Mendonça E.A., Evans J.A., Rzhetsky A. Conflicting biomedical assumptions for mathematical modeling: the case of cancer metastasis. PLoS Comput Biol 2011, 7(10):e1002132.
9. Bacac M., Stamenkovic I. Metastatic cancer cell. Annu Rev Pathol 2008, 3:221-247.
10. Bravo-Cordero J.J., Hodgson L., Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol 2012, 24(2):277-283.
11. Entschladen F., Drell T.L., Lang K., Joseph J., Zaenker K.S. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 2004, 5(4):254-258.
12. Entschladen F., Drell T.L., Lang K., Joseph J., Zaenker K.S. Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 2005, 11(3):403-411.
13. Ahmed N., Maines-Bandiera S., Quinn M.A., Unger W.G., Dedhar S., Auersperg N. Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 2006, 290(6):C1532-C1542.
14. Sabbah M., Emami S., Redeuilh G., Julien S., Prévost G., Zimber A., et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 2008, 11(4-5):123-151.
15. Roussos E.T., Condeelis J.S., Patsialou A. Chemotaxis in cancer. Nat Rev Cancer 2011, 11:573-587.
16. Yamaguchi H., Wyckoff J., Condeelis J. Cell migration in tumors. Curr Opin Cell Biol 2005, 17:559-564.
17. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Investig 2009, 119(6):1417-1419.
18. Ohta Y., Suzuki N., Nakamura S., Hartwig J.H., Stossel T.P. The small GTPase RalA targets filamin to induce filopodia. Proc Natl Acad Sci USA 1999, 96(5):2122-2128.
19. Tobler N.E., Detmar M. Tumor and lymph node lymphangiogenesis - impact on cancer metastasis. J Leukoc Biol 2006, 80(4):691-696.
20. Kim Y.N., Koo K.H., Sung J.Y., Yun U.J., Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol 2012, 306879.
21. Smets F.N., Chen Y., Wang L.J., Soriano H.E. Loss of cell anchorage triggers apoptosis (anoikis) in primary mouse hepatocytes. Mol Genet Metab 2002, 75(4):344-352.
22. Mueller B.M., Reisfeld R.A., Edgington T.S., Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992, 89(24):11832-11836.
23. Ebnet K., Vestweber D. Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines. Histochem Cell Biol 1999, 112(1):1-23.
24. Patel K.D., Cuvelier S.L., Wiehler S. Selectins: critical mediators of leukocyte recruitment. Semin Immunol 2002, 14(2):73-81.
25. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014, 15(3):178-196.
26. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2(8):563-572.
27. Radinsky R. Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 1995, 14:323-338.
28. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992, 3(2):65-71.
29. Kollmannsberger C., Hartmann J.T., Kanz L., Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 1998, 124(3-4):207-214.
30. Leone G., Mele L., Pulsoni A., Equitani F., Pagano L. The incidence of secondary leukemias. Haematologica 1999, 84(10):937-945.
31. Maclean A.L., Filippi S., Stumpf M.P. The ecology in the hematopoietic stem cell niche determines the clinical outcome in chronic myeloid leukemia. Proc Natl Acad Sci USA 2014, 111(10):3883-3888.
32. Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009, 114(6):1150-1157.
33. Viadana E., Bross I.D., Pickren J.W. An autopsy study of the metastatic patterns of human leukemias. Oncology 1978, 35(2):87-96.
34. Barcos M., Lane W., Gomez G.A., Han T., Freeman A., Preisler H., et al. An autopsy study of 1206 acute and chronic leukemias (1958 to 1982). Cancer 1987, 60(4):827-837.
35. Kwong Y.L., Chan A.C., Liang R.H. Natural killer cell lymphoma/leukemia: pathology and treatment. Hematol Oncol 1997, 15(2):71-79.
36. Siu L.L., Chan J.K., Kwong Y.L. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol 2002, 17(2):539-554.
37. Orkin S.H., Zon L.I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008, 132(4):631-644.
38. Tenen D.G. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003, 3(2):89-101.
39. Licht J.D., Sternberg D.W. The molecular pathology of acute myeloid leukemia. Hematology 2005, 137-142.
40. Warr M.R., Pietras E.M., Passegué E. Mechanisms controlling hematopoietic stem cell functions during normal hematopoiesis and hematological malignancies. Wiley Interdiscip Rev Syst Biol Med 2011, 3(6):681-701.
41. Carlesso N., Cardoso A.A. Stem cell regulatory niches and their role in normal and malignant hematopoiesis. Curr Opin Hematol 2010, 17(4):281-286.
42. Buss E.C., Ho A.D. Leukemia stem cells. Int J Cancer 2011, 129(10):2328-2336.
43. Pandolfi A., Barreyro L., Steidl U. Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl Med 2013, 2(2):143-150.
44. Guzman M.L., Jordan C.T. Considerations for targeting malignant stem cells in leukemia. Cancer Control 2004, 11(2):97-104.
45. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009, 9(1):15-27.
46. Shankland K.R., Armitage J.O., Hancock B.W. Non-Hodgkin lymphoma. Lancet 2012, 380(9844):848-857.
47. McDonnell P.J., Mann R.B., Bulkley B.H. Involvement of the heart by malignant lymphoma: a clinicopathologic study. Cancer 1982, 49(5):944-951.
48. Tsimberidou A.M., Keating M.J. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005, 103(2):216-228.
49. Tsimberidou A.M., Keating M.J. Richter's transformation in chronic lymphocytic leukemia. Semin Oncol 2006, 33(2):250-256.
50. Omoti C.E., Omoti A.E. Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol 2008, 142(5):709-716.
51. Swords R., Bruzzi J., Giles F. Recent advances in the diagnosis and therapy of Richter's syndrome. Med Oncol 2007, 24(1):17-32.
52. Bishop P.C., Wilson W.H., Pearson D., Janik J., Jaffe E.S., Elwood P.C. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999, 17(8):2479-2485.
53. Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005, 5(4):251-262.
54. Shaffer A.L., Young R.M., Staudt L.M. Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012, 30:565-610.
55. Dyer M.J. The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies. Int J Hematol 2003, 77(4):315-320.
56. Brecher M., Banks P.M. Hodgkin's disease variant of Richter's syndrome. Report of eight cases. Am J Clin Pathol 1990, 93(3):333-339.
57. Vasilj A., Kojić-Katović S., Maricević I., Zokvić E., Kelcec I.B., Tomas D., et al. Hodgkin's lymphoma variant of Richter's syndrome. Coll Antropol 2010, 34(1):295-299.
58. Trendowski M. The promise of sonodynamic therapy. Cancer Metastasis Rev 2014, 33(1):143-160.
59. Rosenthal I., Sostaric J.Z., Riesz P. Sonodynamic therapy - a review of the synergistic effects of drugs and ultrasound. Ultrason Sonochem 2004, 11(6):349-363.
60. Bai W., Shen E., Hu B. Induction of the apoptosis of cancer cell by sonodynamic therapy: a review. Chin J Cancer Res 2012, 24(4):368-373.
61. Meng Q., Chen B., Wu W., Shao Z., Gao F., Zhao H. Enhanced antitumor effects of low-frequency ultrasound combined with adriamycin on human leukemia multidrug resistance cell line K562/A02. Chin J Cancer Res 2008, 27(11):436-439.
62. Trendowski M., Wong V., Acquafondata C., Christen T., Fondy T.P. The real deal: using cytochalasin B in sonodynamic therapy to preferentially damage leukemia cells. Anticancer Res 2014, 34:2195-2202.
63. Su X., Wang P., Wang X., Cao B., Li L., Liu Q. Apoptosis of U937 cells induced by hematoporphyrin monomethyl ether-mediated sonodynamic action. Cancer Biother Radiopharm 2013, 28:207-217.
64. Liang L., Xie S., Jiang L., Jin H., Li S., Liu J. The combined effects of hematoporphyrin monomethyl ether-SDT and doxorubicin on the proliferation of QBC939 cell lines. Ultrasound Med Biol 2013, 39(1):146-160.
65. Miller M.W., Luque A.E., Battaglia L.F., Mazza S., Everbach E.C. Biological and environmental factors affecting ultrasound-induced hemolysis in vitro: 1. HIV macrocytosis. Ultrasound Med Biol 2003, 29(1):77-91.
66. Cordeiro E.R., Cathelineau X., Thüroff S., Marberger M., Crouzet S., de la Rosette J.J. High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJU Int 2012, 110(9):1228-1242.
67. Chu K.F., Dupuy D.E. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 2014, 14(3):199-208.
68. Semins M.J., Trock B.J., Matlaga B.R. The effect of shock wave rate on the outcome of shock wave lithotripsy: a meta-analysis. J Urol 2008, 179(1):194-197.
69. Pace K.T., Ghiculete D., Harju M., Honey R.J. Shock wave lithotripsy at 60 or 120 shocks per minute: a randomized, double-blind trial. J Urol 2005, 174(2):595-599.
70. Verna E.C., Dhar V. Endoscopic ultrasound-guided fine needle injection for cancer therapy: the evolving role of therapeutic endoscopic ultrasound. Ther Adv Gastroenterol 2008, 1(2):103-109.
71. Yan B.M., Van Dam J. Endoscopic ultrasound-guided intratumoural therapy for pancreatic cancer. Can J Gastroenterol 2008, 22(4):405-410.
72. Chan H.H., Nishioka N.S., Mino M., Lauwers G.Y., Puricelli W.P., Collier K.N., et al. EUS-guided photodynamic therapy of the pancreas: a pilot study. Gastrointest Endosc 2004, 59(1):95-99.
73. Yusuf T.E., Matthes K., Brugge W.R. EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcine model (with video). Gastrointest Endosc 2008, 67(6):957-961.
74. O'Neill F.J. Selective destruction of cultured tumor cells with uncontrolled nuclear division by cytochalasin B and cytosine arabinoside. Cancer Res 1975, 35(11 Pt 1):3111-3115.
75. Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 2005, 4(3):283-293.
76. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011, 61(4):250-281.
77. Brown S.B., Brown E.A., Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004, 5(8):497-508.
78. Kolber M.A., Hill P. Vincristine potentiates cytochalasin B-induced DNA fragmentation in vitro. Cancer Chemother Pharmacol 1992, 30(4):286-290.